Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Bio Sequence
2 min read
Strategy for Retrieving Bispecific Antibody Sequences
19 September 2023
Using the Patsnap Bio Sequence Database for bispecific antibody sequence retrieval is recommended.
Drug Insights
4 min read
An In-depth Analysis of Thioguanine's R&D Progress and Mechanism of Action on Drug Target
19 September 2023
This article summarized the latest R&D progress of Thioguanine, the Mechanism of Action for Thioguanine, and the drug target R&D trends for Thioguanine.
Latest Hotspot
3 min read
Edgewise Therapeutics commences Phase 1 human trial for EDG-7500, a promising treatment for Hypertrophic Cardiomyopathy and severe Cardiac Diastolic Dysfunction
19 September 2023
Edgewise Therapeutics initiates its first-in-human Phase 1 trial for EDG-7500, the primary clinical contender for Hypertrophic Cardiomyopathy and other severe Cardiac Diastolic Dysfunction conditions.
Drug Insights
4 min read
Stavudine: Detailed Review of its Transformative R&D Success
19 September 2023
This article summarized the latest R&D progress of Stavudine, the Mechanism of Action for Stavudine, and the drug target R&D trends for Stavudine.
Advanced Tech.
10 min read
"Super drugs" for treating cancer and AIDS: Chemokines family
19 September 2023
Chemokines, also known as chemotactic cytokines, are a group of factors that, in conjunction with their cell surface receptors, induce the directed migration of leukocytes.
Drug Insights
4 min read
Quinidine Gluconate Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Quinidine Gluconate, the Mechanism of Action for Quinidine Gluconate, and the drug target R&D trends for Quinidine Gluconate.
Latest Hotspot
4 min read
The NC318 Phase 2 trial, in Combination with Pembrolizumab, shows clinical activity in treating patients with advanced NSCLC
19 September 2023
NextCure Inc. and Yale Cancer Center announced Phase 2 trial results today, indicating a combined NC318 and Pembrolizumab regimen is beneficial for advanced non-responsive PD-1 non-small cell lung cancer patients.
Drug Insights
4 min read
Unleashing the Power of Proparacaine Hydrochloride: A Comprehensive Review on R&D Breakthroughs
19 September 2023
This article summarized the latest R&D progress of Proparacaine Hydrochloride, the Mechanism of Action for Proparacaine Hydrochloride, and the drug target R&D trends for Proparacaine Hydrochloride.
Valuable Targets
6 min read
Targeting 5-lipoxygenase - Leukotriene inhibitor
19 September 2023
Leukotrienes are a group of inflammatory mediators produced by the metabolism of arachidonic acid (AA) through the 5-lipoxygenase (5-LO) pathway, featuring a conjugated triene structure of a 20-carbon unsaturated acid.
Drug Insights
4 min read
A Comprehensive Review of Pralidoxime Chloride's R&D Innovations
19 September 2023
This article summarized the latest R&D progress of Pralidoxime Chloride, the Mechanism of Action for Pralidoxime Chloride, and the drug target R&D trends for Pralidoxime Chloride.
Latest Hotspot
3 min read
Myeloid Therapeutics begins administering MT-302, a new TROP2-focusing RNA CAR, for advanced or metastatic epithelial tumors
19 September 2023
Myeloid Therapeutics, a clinical-stage cancer treatment company, has given the first dose of MT-302 to a patient in a Phase 1 trial for advanced or metastatic epithelial tumors.
Drug Insights
4 min read
Pharmaceutical Insights: Phenylpropanolamine Hydrochloride's R&D Progress
19 September 2023
This article summarized the latest R&D progress of Phenylpropanolamine Hydrochloride, the Mechanism of Action for Phenylpropanolamine Hydrochloride, and the drug target R&D trends for Phenylpropanolamine Hydrochloride.